RESUMO
PURPOSE: Osteopontin (OPN) is evolving as a novel biomarker of injury, overall survival and renal outcome in critically ill patients with acute kidney injury (AKI), requiring renal replacement therapy. METHODS: We performed a prospective study on 35 consecutive patients of acute kidney injury requiring renal replacement therapy (AKIN stage 3). OPN levels were measured in the patients and in the controls. The relation between OPN and the severity of illness and its effect on the AKI and renal outcome were studied. RESULTS: There was a statistically significant elevation of OPN in patients of AKIN stage 3 in comparison to healthy controls (p = 0.001). The Sequential Organ Function Assessment (SOFA) scores were found to be higher in septic group in comparison to non-septic group and it was statistically significant (p = 0.014). There was significant correlation between SOFA scoring and OPN levels suggesting its association with severity (r = 0.382, p = 0.023). CONCLUSIONS: In our study, OPN was found to be a valuable marker of severity of injury, its association with sepsis and renal recovery, in patients with acute kidney injury needing renal replacement therapy.
Assuntos
Injúria Renal Aguda/sangue , Injúria Renal Aguda/terapia , Osteopontina/sangue , Diálise Renal , Adulto , Idoso , Feminino , Humanos , Índia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Centros de Atenção Terciária , Adulto JovemRESUMO
Early trials of tacrolimus in renal transplant recipients have not revealed hearing loss as an adverse effect. Here, we present a case report and a review of the literature of deafness after tacrolimus use. The review of the literature and our experience suggested that the possible reason for hearing loss could be due to an initiation of a sudden spike in the tacrolimus serum level, which was later worsened by its cumulative toxic effect.
